Perspective - (2025) Volume 11, Issue 6
Received: 01-Dec-2025, Manuscript No. antimicro-26-183061;
Editor assigned: 03-Dec-2025, Pre QC No. P-183061;
Reviewed: 17-Dec-2025, QC No. Q-183061;
Revised: 22-Dec-2025, Manuscript No. R-183061;
Published:
29-Dec-2025
Citation: Kimura, Hana. ”Long-acting Antimicrobials: Combating Resistance, Improving Care.” J Antimicrob Agents 11 (2025):436.
Copyright: © 2025 Kimura H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The field of antimicrobial therapy is undergoing a significant transformation driven by the urgent need to combat growing antimicrobial resistance and improve patient outcomes. A key area of innovation involves the development of long-acting antimicrobial formulations, which aim to overcome the limitations of conventional short-acting drugs. These advanced delivery systems are designed to maintain therapeutic drug concentrations for extended periods, thereby enhancing efficacy and patient compliance. One promising approach is the creation of novel carrier systems, such as nanoparticles and microparticles, which can facilitate targeted drug delivery and improve bioavailability, addressing challenges like rapid drug clearance and poor absorption [1].
Injectable sustained-release formulations are also a focus of research, particularly those utilizing polymer-based drug delivery systems. These systems allow for the encapsulation of antimicrobial agents, creating depots that provide prolonged therapeutic drug levels. This is especially valuable for treating chronic infections that require extended therapy, offering a means to reduce the frequency of administration and improve overall patient outcomes [2].
Nanotechnology offers a powerful toolkit for developing innovative long-acting antimicrobial agents. Nanoparticles, including liposomes, polymeric nanoparticles, and solid lipid nanoparticles, can be engineered to enhance drug solubility, improve targeting to infection sites, and meticulously control drug release kinetics. This advanced approach has the potential to significantly boost the efficacy of antimicrobial treatments while concurrently minimizing adverse side effects [3].
The fabrication of biodegradable microspheres represents another important strategy in the development of sustained-release antimicrobial formulations. Utilizing materials like poly(lactic-co-glycolic acid) (PLGA), these microspheres can be designed to encapsulate drugs such as fluoroquinolones, providing prolonged therapeutic effects. This method not only aids in improving treatment adherence but also plays a crucial role in mitigating the risk of developing antimicrobial resistance [4].
Hydrogel-based drug delivery systems are emerging as highly versatile platforms for long-acting antimicrobial applications. Their inherent biocompatibility and capacity to encapsulate a wide spectrum of drugs, coupled with their controlled release properties, make them ideal for various therapeutic scenarios. Hydrogels are particularly suited for localized infections and for delivering antibiotics over extended durations, thus enhancing treatment effectiveness and patient comfort [5].
In situ forming implants offer an innovative method for sustained antibiotic delivery. These systems involve the injection of a liquid formulation that solidifies within the body, forming a drug-releasing depot. Research into these implants examines their pharmacokinetic profiles and demonstrated efficacy against bacterial infections, underscoring their potential to significantly improve patient compliance and alleviate the burden associated with frequent dosing schedules [6].
Lipid-based nanoparticles are being explored for their potential in long-acting oral delivery of antifungal agents. These formulations aim to enhance oral bioavailability and prolong drug circulation times, offering a promising avenue for improving the treatment of systemic fungal infections through less frequent dosing regimens [7].
Antimicrobial polymers are also being designed for sustained release applications, contributing to advancements in antimicrobial drug delivery. These polymers can be incorporated into various devices, including coatings and implants, to provide prolonged protection against microbial colonization and infection, finding particular utility in medical devices and wound care [8].
Mesoporous silica nanoparticles (MSNs) present a unique platform for the controlled release of antibiotics. Their substantial surface area and adjustable pore size facilitate efficient drug loading and enable precise control over sustained release kinetics. MSN-based formulations have demonstrated effectiveness in combating bacterial infections, paving the way for new long-acting antimicrobial therapies [9].
Finally, the development of implantable drug delivery devices is crucial for chronic antimicrobial therapy. Biodegradable implants designed for the slow release of antibiotics can prevent infections, such as those at surgical sites. These localized, long-term delivery systems maintain effective therapeutic concentrations while minimizing systemic exposure, offering a significant advantage in managing chronic infections [10].
Advanced long-acting antimicrobial formulations are revolutionizing infection management by extending drug presence at the target site and improving patient adherence. Innovative carrier systems like nanoparticles and microparticles are central to these advancements, addressing challenges such as rapid drug clearance and poor bioavailability to enhance therapeutic efficacy [1].
Injectable sustained-release systems, particularly those employing polymer-based drug delivery technologies, are critical for prolonging antimicrobial drug levels. These polymeric micelles and depots are vital for treating chronic infections requiring extended therapeutic interventions, thereby simplifying treatment regimens and improving patient outcomes [2].
Nanotechnology is instrumental in creating sophisticated long-acting antimicrobial delivery systems. Nanoparticles, including liposomes and polymeric variants, are engineered to optimize drug solubility, enhance targeting to infection foci, and precisely modulate drug release rates, thereby increasing treatment effectiveness and reducing side effects [3].
The fabrication of biodegradable microspheres is a cornerstone of sustained-release antimicrobial strategies. These micro-scale delivery vehicles, often made from biocompatible polymers like PLGA, are designed to provide a prolonged therapeutic effect, which is essential for improving patient compliance and combating the development of antimicrobial resistance [4].
Hydrogel-based drug delivery systems offer a versatile and biocompatible platform for sustained antimicrobial therapy. Their ability to encapsulate diverse drugs and control release kinetics makes them suitable for localized treatments and prolonged antibiotic administration, leading to enhanced efficacy and patient comfort [5].
In situ forming implants represent a cutting-edge technology for sustained antibiotic delivery, transforming chronic antimicrobial therapy. By forming a drug-releasing depot within the body, these implants ensure consistent therapeutic drug levels, significantly improving patient compliance and reducing the need for frequent administration [6].
Lipid-based nanoparticles are being developed to overcome limitations in oral drug delivery for antifungal agents. These nanocarriers are designed to improve oral bioavailability and extend drug circulation, offering a more effective approach to treating systemic fungal infections with reduced dosing frequency [7].
Antimicrobial polymers are a significant area of development for sustained release applications, particularly in medical devices and wound care. Their incorporation into coatings and implants provides long-lasting protection against microbial colonization and infections, enhancing the durability of antimicrobial interventions [8].
Mesoporous silica nanoparticles (MSNs) are emerging as highly effective platforms for sustained antibiotic delivery due to their unique porous structure. Their high surface area and tunable pore sizes allow for efficient drug loading and controlled release, demonstrating efficacy in combating bacterial infections and supporting long-acting therapeutic strategies [9].
Implantable drug delivery systems are pivotal for chronic antimicrobial therapy, offering localized and sustained antibiotic release. Biodegradable implants, for instance, can effectively prevent infections like surgical site infections by maintaining therapeutic concentrations over extended periods, thereby minimizing systemic exposure and its associated risks [10].
This collection of research highlights advancements in long-acting antimicrobial formulations designed to combat drug resistance and improve patient care. Innovations include the use of nanoparticles, microparticles, polymer-based systems, hydrogels, and in situ forming implants to achieve sustained drug release. These technologies aim to enhance drug delivery, bioavailability, and targeting to infection sites, leading to improved therapeutic efficacy and reduced dosing frequency. Biodegradable microspheres and implants offer prolonged effects, while nanotechnology and antimicrobial polymers provide new avenues for localized and durable protection against infections. Overall, these developments promise to significantly enhance the effectiveness of antimicrobial treatments and address critical challenges in infectious disease management.
None
None
Journal of Antimicrobial Agents received 444 citations as per Google Scholar report
